 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Versicor Inc.
 |
Versicor Inc. |
 |
 |
 |
PROFILE |
 |
Versicor develops pharmaceuticals to treat fungal and bacterial infections. Its lead drug candidate is V-Echinocandin, which prevents cell wall formation in "Candida" and other infectious fungi. Another potential drug is V-Glycopeptide, an antibiotic to treat bacterial infections in hospital patients. Versicor plans to market these drugs directly to hospitals. The company is also developing a new class of antibiotics with Pharmacia, as well as deformylase inhibitors, which target unique enzymes in bacteria, with Novartis. BIOCOR, a partnership between Versicor and Biosearch Italia, develops new drug candidates. Director John Cavanaugh owns more than 10% of the firm through HealthCare Ventures.
COMPETITION |
 |
Cubist Pharmaceuticals, Inc. (CBST)
IntraBiotics Pharmaceuticals, Inc. (IBPI)
Microcide Pharmaceuticals, Inc. (MCDE)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 5.90
1-Yr. Sales Growth: 37.2%
Employees: 41
Revenue per employee: $143,902.44
KEY PEOPLE |
 |
George F. Horner
CEO
Dov A. Goldstein
CFO
CONTACT INFO |
 |
34790 Ardentech Ct.
Fremont, CA 94555
US
Phone: 510-739-3000
Fax: 510-739-3003
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |